Privium Fund Management’s Lexeo Therapeutics LXEO Stock Holding History

Privium Fund Management’s Portfolio LXEO Stock Details LXEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.18M	Buy	205,000 +12,450	+6%	+$88.2K	0.25%	41
2025 Q4	$1.91M	Buy	192,550 +194	+0.1%	+$1.77K	0.35%	33
2025 Q3	$1.28M	Buy	192,356 +14,000	+8%	+$67.7K	0.23%	38
2025 Q2	$753K	Buy	178,356 +18,158	+11%	+$59.7K	0.16%	39
2025 Q1	$556K	Buy	160,198 +22,083	+16%	+$97.8K	0.14%	40
2024 Q4	$909K	Buy	+138,115	New	+$1.09M	0.21%	35

Other funds holding LXEO

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Privium Fund Management's LXEO Position: Q1 2026 in Review

Privium Fund Management increased its Lexeo Therapeutics (LXEO) stake by 6.5% in Q1 2026, buying an estimated $88.2K and bringing the position to 205,000 shares worth $1.18M. The position accounts for 0.25% of the portfolio, ranked #41.

Privium Fund Management first reported a position in LXEO in Q4 2024 and has held it in 6 quarters since. The position peaked at $1.91M in Q4 2025. 139 funds tracked by Wall St. Rank hold LXEO as of Q1 2026.

Privium Fund Management held 205,000 shares of Lexeo Therapeutics worth $1.18M as of Q1 2026.
Privium Fund Management bought 12,450 Lexeo Therapeutics shares in Q1 2026, an estimated $88.2K.
Lexeo Therapeutics made up 0.25% of Privium Fund Management's portfolio in Q1 2026, its #41 holding.
Privium Fund Management first reported a position in Lexeo Therapeutics in Q4 2024 and has held it in 6 quarters since.
Privium Fund Management's Lexeo Therapeutics position peaked at $1.91M in Q4 2025.
139 funds tracked by Wall St. Rank held Lexeo Therapeutics as of Q1 2026.

Based on Privium Fund Management's 13F filing for Q1 2026, filed 5 May 2026.